

Contents

ABOUT THE EDITORS — v

HISTORICAL DEVELOPMENT
AND PERSPECTIVES OF THE SERIES — vii

PREFACE TO VOLUME 19 — ix

CONTRIBUTORS TO VOLUME 19 — xix

TITLES OF VOLUMES 1–44 IN THE
METAL IONS IN BIOLOGICAL SYSTEMS SERIES — xxiii

CONTENTS OF VOLUMES IN THE
METAL IONS IN LIFE SCIENCES SERIES — xxv

Peggy L. Carver

1 METALS IN MEDICINE: THE THERAPEUTIC USE OF METAL IONS IN THE CLINIC — 1

Abstract — 2

1. Introduction — 2
2. Metal-Related Diseases — 4
3. Metals as Medicines — 5
4. Metal Ion Toxicology — 10
5. Concluding Remarks — 11

Abbreviations — 11

References — 11

Anne Robert, Françoise Benoit-Vical, Yan Liu, and Bernard Meunier

2 SMALL MOLECULES: THE PAST OR THE FUTURE IN DRUG INNOVATION? — 17

Abstract — 18

1. Introduction — 18
2. Brief Historical Overview of Chemical Drug Development — 19
3. Trioxaquines: Antimalarial Hybrid Molecules with a Dual Mode of Action — 28

- 4. Regulation of Copper Homeostasis in Alzheimer's Disease — 34
- 5. General Conclusions — 42
- Acknowledgments — 42
- Abbreviations and Definitions — 42
- References — 42

Guido Crisponi, Valeria M. Nurchi, and Joanna I. Lachowicz

3 IRON CHELATION FOR IRON OVERLOAD IN THALASSEMIA — 49

- Abstract — 50
- 1. Introduction — 50
- 2. Overview on Thalassemias — 51
- 3. Iron Chelation Therapy — 55
- 4. Chelators in Use — 58
- 5. Combination Therapy — 74
- 6. New Chelators — 75
- 7. Concluding Remarks — 79
- Acknowledgments — 80
- Abbreviations and Definitions — 80
- References — 81

Roberta J. Ward and Robert R. Crichton

4 IRONING OUT THE BRAIN — 87

- Abstract — 88
- 1. Iron Homeostasis in the Brain — 88
- 2. Neurodegenerative Diseases, Disruption of Iron Homeostasis, and Iron Speciation — 101
- 3. Iron and the Immune System — 108
- 4. Iron Chelation Present and Future Directions — 112
- 5. Concluding Remarks — 114
- Abbreviations — 115
- References — 117

Manfred Nairz and Guenter Weiss

5 INFECTIONS ASSOCIATED WITH IRON ADMINISTRATION — 123

- Abstract — 124
- 1. Introduction — 124
- 2. Iron, Immune Function, and Infection — 129
- 3. Iron Administration and Infection — 135
- 4. Concluding Remarks and Suggestions for Future Research — 143
- Acknowledgments — 143
- Abbreviations — 143
- References — 145

Amy Barton Pai

- 6 IRON OXIDE NANOPARTICLE FORMULATIONS FOR SUPPLEMENTATION — 157**
Abstract — 158
1. Introduction — 158
 2. Structure and Biodistribution of Intravenous Iron Formulations — 159
 3. Therapeutic Efficacy in the Dialysis Population — 164
 4. Adverse Safety Signals — 167
 5. Concluding Remarks: Gaps in Regulatory Science for Intravenous Iron Formulations — 174
- Abbreviations — 176
References — 176

Elzbieta Gumienna-Kontecka and Peggy L. Carver

- 7 BUILDING A TROJAN HORSE: SIDEROPHORE-DRUG CONJUGATES FOR THE TREATMENT OF INFECTIOUS DISEASES — 181**
Abstract — 182
1. Introduction — 182
 2. Overview of Siderophores — 183
 3. Siderophore Antimicrobial Conjugates — 191
 4. Use of Siderophore-Drug Conjugates to Alter the Spectrum of Activity of an Antimicrobial — 197
 5. Lessons Learned from the Development of Antibacterial Siderophore Drug Conjugates — 198
 6. Concluding Remarks — 199
- Acknowledgment — 200
Abbreviations — 200
References — 200

Debbie C. Crans, LaRee Henry, Gabriel Cardiff, and Barry I. Posner

- 8 DEVELOPING VANADIUM AS AN ANTIDIABETIC OR ANTICANCER DRUG: A CLINICAL AND HISTORICAL PERSPECTIVE — 203**
Abstract — 204
1. Introduction: Antidiabetic Vanadium-Containing Compounds — 204
 2. Biological Activities of Vanadium Compounds — 209
 3. Human Studies with Vanadium Compounds — 214
 4. Commercialization of Vanadium as Antidiabetic Agent — 219
 5. What is Next? — 221
 6. Conclusions and Outlook — 224
- Acknowledgment — 225
Abbreviations — 225
References — 225

Wolfgang Maret

9 CHROMIUM SUPPLEMENTATION IN HUMAN HEALTH, METABOLIC SYNDROME, AND DIABETES — 231

Abstract — 232

1. The Nature of Essential Chemical Elements — 232
2. Chromium in Mammalian Biology — 235
3. Redox and Coordination Chemistry of Chromium Relevant to Biology — 237
4. Chromium Metabolism — 239
5. Low-Molecular-Weight Biological Chromium Complexes — 240
6. Chromium Toxicity — 241
7. Chromium in Diabetes and Metabolic Syndrome — 243
8. Possible Resolution of Controversies in Chromium Biology — 246

Acknowledgment — 248

Abbreviations — 248

References — 248

Keith M. Erikson and Michael Aschner

10 MANGANESE: ITS ROLE IN DISEASE AND HEALTH — 253

Abstract — 254

1. Introduction — 254
2. Manganese Essentiality — 255
3. Factors Involved in Manganese Status — 257
4. Manganese Neurotoxicity — 260
5. Conclusions — 262

Acknowledgment — 262

Abbreviations — 262

References — 263

Elizabeth A. Bajema, Kaleigh F. Roberts, and Thomas J. Meade

11 COBALT-SCHIFF BASE COMPLEXES: PRECLINICAL RESEARCH AND POTENTIAL THERAPEUTIC USES — 267

Abstract — 268

1. Introduction — 268
2. Antimicrobial Activity — 269
3. Antiviral Activity — 275
4. Anticancer Activity — 276
5. Inhibiting Aggregation of Amyloid- β — 284
6. Conclusions — 293

Acknowledgments — 294

Abbreviations and Definitions — 294

References — 295

Jay Lopez, Divya Ramchandani, and Linda Vahdat

12 COPPER DEPLETION AS A THERAPEUTIC STRATEGY IN CANCER — 303

Abstract — 304

1. Introduction — 304

2. Metals — **304**
 3. Copper Homeostasis in Pathophysiology — **307**
 4. Copper in Cancer — **309**
 5. Preclinical Studies — **314**
 6. Clinical Trials of Copper Depletion in Cancer — **318**
 7. Concluding Remarks and Future Directions — **320**
- Acknowledgments — **320**
Abbreviations — **321**
References — **322**

Dinorah Gambino and Lucía Otero

13 METAL COMPOUNDS IN THE DEVELOPMENT OF ANTIPARASITIC AGENTS: RATIONAL DESIGN FROM BASIC CHEMISTRY TO THE CLINIC — 331

Abstract — **332**

1. Introduction — **332**
2. Rational Design of Prospective Agents — **337**
3. Identification and Validation of Parasite Targets — **347**
4. Metallomics in Parasites — **349**
5. Preclinical Studies — **350**
6. Concluding Remarks and Perspectives — **352**

Acknowledgments — **353**

Abbreviations — **353**

References — **354**

Sigridur G. Suman and Johanna M. Gretarsdottir

14 CHEMICAL AND CLINICAL ASPECTS OF METAL-CONTAINING ANTIDOTES FOR POISONING BY CYANIDE — 359

Abstract — **360**

1. Introduction — **360**
2. Naturally Occurring Cyanide — **362**
3. Poisoning by Cyanide — **367**
4. Metal-Containing Antidotes — **372**
5. Concluding Remarks — **385**

Acknowledgment — **386**

Abbreviations and Definitions — **386**

References — **386**

SUBJECT INDEX — 393